AZP-3800

**AZP-3800** is an investigational preclinical **small peptide therapeutic family** being developed by **Amolyt Pharma** for **acromegaly**, a disorder driven by excess growth hormone secretion. Based on the available context, AZP-3800 refers to an early discovery-stage peptide series from which Amolyt was selecting a lead candidate, rather than a single clinically characterized molecule. The program appears to belong to Amolyt's acromegaly franchise of peptide **growth hormone receptor antagonist** candidates, intended to reduce growth hormone signaling and downstream insulin-like growth factor 1 activity; however, the exact lead structure, final clinical candidate identity, and detailed pharmacologic profile for AZP-3800 itself are not clearly disclosed in the available source material.